{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:47:13Z","timestamp":1792291633534,"version":"4.4.0"},"reference-count":32,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3,1]]},"abstract":"\n BACKGROUND:<\/jats:title>\n Since mid-2006, human papillomavirus (HPV) vaccination has been recommended for females aged 11 to 12 years and through 26 years if not previously vaccinated.<\/jats:p>\n <\/jats:sec>\n \n METHODS:<\/jats:title>\n HPV DNA prevalence was analyzed in cervicovaginal specimens from females aged 14 to 34 years in NHANES in the prevaccine era (2003\u20132006) and 4 years of the vaccine era (2009\u20132012) according to age group. Prevalence of quadrivalent HPV vaccine (4vHPV) types (HPV-6, -11, -16, and -18) and other HPV type categories were compared between eras. Prevalence among sexually active females aged 14 to 24 years was also analyzed according to vaccination history.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n Between the prevacccine and vaccine eras, 4vHPV type prevalence declined from 11.5% to 4.3% (adjusted prevalence ratio [aPR]: 0.36 [95% confidence interval (CI): 0.21\u20130.61]) among females aged 14 to 19 years and from 18.5% to 12.1% (aPR: 0.66 [95% CI: 0.47\u20130.93]) among females aged 20 to 24 years. There was no decrease in 4vHPV type prevalence in older age groups. Within the vaccine era, among sexually active females aged 14 to 24 years, 4vHPV type prevalence was lower in vaccinated (\u22651 dose) compared with unvaccinated females: 2.1% vs 16.9% (aPR: 0.11 [95% CI: 0.05\u20130.24]). There were no statistically significant changes in other HPV type categories that indicate cross-protection.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS:<\/jats:title>\n Within 6 years of vaccine introduction, there was a 64% decrease in 4vHPV type prevalence among females aged 14 to 19 years and a 34% decrease among those aged 20 to 24 years. This finding extends previous observations of population impact in the United States and demonstrates the first national evidence of impact among females in their 20s.<\/jats:p>\n <\/jats:sec>","DOI":"10.1542\/peds.2015-1968","type":"journal-article","created":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T21:13:27Z","timestamp":1456175607000},"source":"Crossref","is-referenced-by-count":284,"title":["Prevalence of HPV After Introduction of the Vaccination Program in the United States"],"prefix":"10.1542","volume":"137","author":[{"given":"Lauri E.","family":"Markowitz","sequence":"first","affiliation":[{"name":"Division of STD Prevention, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of STD Prevention, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hariri","sequence":"additional","affiliation":[{"name":"Division of STD Prevention, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Steinau","sequence":"additional","affiliation":[{"name":"Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen F.","family":"Dunne","sequence":"additional","affiliation":[{"name":"Division of STD Prevention, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Unger","sequence":"additional","affiliation":[{"name":"Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2016,3,1]]},"reference":[{"issue":"9580","key":"2021120919111729200_B1","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"19","key":"2021120919111729200_B2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.","volume":"356","author":"FUTURE II Study Group","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"2021120919111729200_B3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"2021120919111729200_B4","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep"},{"issue":"29","key":"2021120919111729200_B5","first-page":"620","article-title":"Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014\u2014United States.","volume":"63","author":"Stokley","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"2021120919111729200_B6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/jit192","article-title":"Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.","volume":"208","author":"Markowitz","year":"2013","journal-title":"J Infect Dis"},{"issue":"29","key":"2021120919111729200_B7","first-page":"591","article-title":"Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013\u2014United States.","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"2021120919111729200_B8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States.","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"issue":"4","key":"2021120919111729200_B9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/infdis\/jir341","article-title":"Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006.","volume":"204","author":"Hariri","year":"2011","journal-title":"J Infect Dis"},{"issue":"7","key":"2021120919111729200_B10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"2021120919111729200_B11","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines.","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"issue":"130","key":"2021120919111729200_B12","first-page":"1","article-title":"Design and estimation for the National Health Interview Survey, 1995-2004.","year":"2000","journal-title":"Vital Health Stat 2"},{"issue":"9","key":"2021120919111729200_B13","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.2105\/AJPH.81.9.1166","article-title":"Epidemiologic studies utilizing surveys: accounting for the sampling design.","volume":"81","author":"Korn","year":"1991","journal-title":"Am J Public Health"},{"issue":"5","key":"2021120919111729200_B14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/aje\/kwp440","article-title":"Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data.","volume":"171","author":"Bieler","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"5","key":"2021120919111729200_B15","first-page":"95","article-title":"Noninfluenza vaccination coverage among adults\u2014United States, 2012.","volume":"63","author":"Williams","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"2021120919111729200_B16","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"2021120919111729200_B17","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/sextrans-2011-050234","article-title":"The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme.","volume":"87","author":"Read","year":"2011","journal-title":"Sex Transm Infect"},{"issue":"7","key":"2021120919111729200_B18","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.","volume":"199","author":"Wheeler","year":"2009","journal-title":"J Infect Dis"},{"issue":"1","key":"2021120919111729200_B19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"2021120919111729200_B20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jnci\/92.6.464","article-title":"Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica.","volume":"92","author":"Herrero","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2021120919111729200_B21","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1038\/bjc.2014.198","article-title":"Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16\/18 and closely related HPV types.","volume":"110","author":"Kavanagh","year":"2014","journal-title":"Br J Cancer"},{"issue":"1","key":"2021120919111729200_B22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.vaccine.2013.10.085","article-title":"Reduction in HPV 16\/18 prevalence in sexually active young women following the introduction of HPV immunisation in England.","volume":"32","author":"Mesher","year":"2013","journal-title":"Vaccine"},{"issue":"11","key":"2021120919111729200_B23","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices.","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2021120919111729200_B24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease.","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect Agent Cancer"},{"issue":"6","key":"2021120919111729200_B25","doi-asserted-by":"crossref","first-page":"djv086","DOI":"10.1093\/jnci\/djv086","article-title":"US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.","volume":"107","author":"Saraiya","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2021120919111729200_B26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/LGT.0b013e3182a577c7","article-title":"Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction.","volume":"18","author":"Hopenhayn","year":"2014","journal-title":"J Low Genit Tract Dis"},{"issue":"33","key":"2021120919111729200_B27","first-page":"1117","article-title":"National and state vaccination coverage among adolescents aged 13 through 17 years\u2014United States, 2010.","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021120919111729200_B28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/00333549111260S208","article-title":"Validity of parent-reported vaccination status for adolescents aged 13-17 years: National Immunization Survey-Teen, 2008.","volume":"126","author":"Dorell","year":"2011","journal-title":"Public Health Rep"},{"issue":"34","key":"2021120919111729200_B29","first-page":"685","article-title":"National and state vaccination coverage among adolescents aged 13-17 years\u2014United States, 2012.","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"17","key":"2021120919111729200_B30","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"2021120919111729200_B31","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/cid\/civ364","article-title":"Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: a nationwide study of 550,000 young girls.","volume":"61","author":"Blomberg","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2021120919111729200_B32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2015-1968\/926136\/peds_20151968.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2015-1968\/926136\/peds_20151968.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:31:47Z","timestamp":1639096307000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/137\/3\/e20151968\/81400\/Prevalence-of-HPV-After-Introduction-of-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,1]]},"published-print":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2015-1968","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726172739.793532220","asserted-by":"object"}]},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,1]]},"article-number":"e20151968"}}